Servier, Taiho score in phase 3 colorectal cancer trial to support Lonsurf combo nod
Servier and Taiho Oncology are presenting data from a phase 3 trial of cancer treatment Lonsurf which could set it up for a third FDA approval.
Servier and Taiho Oncology are presenting data from a phase 3 trial of cancer treatment Lonsurf which could set it up for a third FDA approval.
